Katherine A. Eade - 24 May 2022 Form 4 Insider Report for HARVARD BIOSCIENCE INC (HBIO)

Reporting relationship: Director
Issuer ticker: HBIO
Reported as of: 24 May 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 May 2022, 16:02:09 UTC
Prior SEC filing: 03 Jan 2022
Next SEC filing: 10 Feb 2023
Source filing: View source filing
Reporting owner signature: /s/ David Sirois, by power of attorney

Key filing fact

Katherine A. Eade filed Form 4 for HARVARD BIOSCIENCE INC (HBIO) on 26 May 2022.

Key facts

This page summarizes Katherine A. Eade's Form 4 filing for HARVARD BIOSCIENCE INC (HBIO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 26 May 2022, 16:02.

Change

Previous filing in this sequence was filed on 03 Jan 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HBIO transaction

Common Stock

Award

Transaction value: $0
Shares: +38,259
Change %: +19%
Price: $0.000000
Shares after: 239,700
Date: 24 May 2022
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents an award of 38,259 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 17, 2022, immediately prior to the commencement of such meeting, and (ii) May 24, 2023.

Footnote F2

Includes (a) the award described in footnote (1) above and (b) 201,441 shares of common stock held by the Reporting Person.